

CERTIFICATE OF MAILING (37 CFR 1.8a)

I hereby certify that this paper (along with any paper referred to as being transmitted therewith) is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Disclosures, Commissioner for Patents, P.O. Box 1450,

Alexandria, VA 22313-1450, on

1-16-07

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Jezia Riley) EXAMINER: Bodepudi, et al

) ART UNIT: 1637 SERIAL NO.: 10/719,257

) Confirmation No. 2800 FILED: November 21, 2003

) Attorney Docket No. 21320-US1 **DETECTABLE LABELED** FOR:

NUCLEOSIDE ANALOGS AND METHODS OF USE THEREOF

INFORMATION DISCLOSURE STATEMENT

Mail Stop Disclosures Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In compliance with the duty of disclosure requirements of 37 C.F.R. \$1.56 1.97 and 1.98, Applicants submit herewith a Form-1449, listing accompanying documents which may be material to the examination of this application.

This Information Disclosure Statement is being filed after the mailing date of the first Office action on the merits.

Accompanying this transmittal is the fee \$180.00, as set forth in 37 C.F.R. 1.17(p) for submission of an information disclosure statement under § 1.97(c). The Commissioner is hereby authorized to charge any fee deficiency, or credit any overpayment, to Deposit Account No. 50-0812.

This Information Disclosure Statement is not to be construed as a representation 01/19/2007 ERYALEWI 0000 that: (i) a search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like

Atty Docket No. 21320-US1 Serial No. 10/719,257 Filing Date: November 21, 2003 Information Disclosure Statement

reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

Consideration of the cited documents and making the same of record in the prosecution of the above-identified application is respectfully requested.

Respectfully submitted,

Date: Jan. 15,2007

Roche Molecular Systems, Inc.

1145 Atlantic Avenue Alameda, CA 94501 Tele: (510) 814-2800

Fax: (510) 814-2973

	IIC D	· · · · · · · · · · · · · · · · · · ·		Atty. Docket No. 21320-US1 Serial No. 10/719,257				
U.S. Department of Commerce				Atty. Docket No. 21320-031	eriai No. 10//19,25/			
LIST OF INFORMATION CITED BY APPLICANT				Applicants: V. Bodepudi, et al.				
(Use several sheets if necessary)				rippinearitis, v. Douchuur, et ai.				
				Filing Date: November 21, 2003 Group: 1637				
JAN 1'9 2007				Filing Date: November 21, 2	Group: 1637		,	
U.S. PATENT DOCUMENTS								
* EXAMPLER INITIAL	MARK!	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS ·	FILING IF APPRO	
	1	5,491,063	02/13/96	Fisher, et al.	435	6	09/01/94	
	2	5,210,051	05/11/93	Gelfand, et al.	435	6	08/06/90	
	3	6,596,856	07/22/03 -	McGall, et al.	536	25.32	02/09/01	
FOREIGN PATENT DOCUMENTS								
7		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
							1.00	
	4	WO 01/16150 A2, A3	03/08/01	PCT	,			
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)								
5 Robs, R., et al., 2000, "Methylene Blue Binding to DNA with Alternating GC Base Sequence: A								
		Modeling Study". J Am Chem Soc., 122 (12):2860-2866						
	6	Yokoyama, N., et al., 1995, "Synthesis and Structure-Activity Relationships of Oxamic Acid and Acetic						
		Acid Derivatives Related to L-Thyronine". J. Med. Chem., 38; 695-707						
EXAMINER DATE CONSIDERED								
*EVALUEED 1 ''.1'C C								
*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in								
conformance and not considered. Include copy of this form with next communication to applicant.								